The frequency of concomitant KRAS or NRAS mutations found in a BRAF-mutated tumor was 4 of 33 (12 %) in NSCLCs, 3 of 34 (8.8 %) in CRCs, or 3 of 67 (4.5 %) in melanomas (Table 3). Here, BRAF is linked to neoplasm.